SCHEMBL10043824

SCHEMBL10043824

CCC(C)NC(=O)Nc1ccc(C)c(-c2cc3cnc(C)cc3n(C)c2=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.40
RAB9A P51151 4/20 0.40
SYK P43405 1/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
KRAS P01116 1/20 0.37
RAF1 P04049 1/20 0.37
BRAF P15056 1/20 0.37
FGFR1 P11362 1/20 0.37
SRC P12931 1/20 0.37
FGFR4 P22455 2/20 0.37
NPC1 O15118 2/20 0.36
EPHX2 P34913 1/20 0.35
KDM4E B2RXH2 2/20 0.34
HPGD P15428 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043829 0.91 SYK (0.41) MAPTRAB9ASYKKRASRAF1
SCHEMBL10043947 0.85 MAPK14 (0.40) RAF1FGFR1SRC
SCHEMBL10043828 0.85 RAB9A (0.48) MAPTRAB9ASYKKRASRAF1
SCHEMBL10043835 0.85 HTR2A (0.43) MAPTRAB9ASYKKRASRAF1
SCHEMBL10043858 0.85 SYK (0.40) MAPTALDH1A1RAB9ASYKKRAS
SCHEMBL10043865 0.84 SYK (0.38) MAPTRAB9ASYKKRASRAF1
SCHEMBL854868 0.84 SYK (0.38) MAPTALDH1A1RAB9ASYKKRAS
SCHEMBL10043821 0.84 SYK (0.49) MAPTRAB9ASYKFGFR1SRC
SCHEMBL12400251 0.83 SYK (0.39) MAPTRAB9ASYKKRASRAF1
SCHEMBL10043718 0.83 ALDH1A1 (0.47) MAPTALDH1A1RAB9ASYKFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPT 2514/4885ALDH1A1 4274/4885RAB9A 1818/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPT 2514/4885ALDH1A1 4274/4885RAB9A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.